SCHEMBL4318604

SCHEMBL4318604

O=C(c1cc2cc(Cl)ccc2[nH]1)N1C[C@H]2CCCN[C@H]2C1

nearest known ligand 0.65

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 8/20 0.65
HRH3 Q9Y5N1 4/20 0.65
HRH1 P35367 1/20 0.54
KMT2A Q03164 7/20 0.50
MEN1 O00255 5/20 0.50
RAB9A P51151 1/20 0.50
ATM Q13315 1/20 0.50
RXFP1 Q9HBX9 1/20 0.49
POLB P06746 1/20 0.48
PARP1 P09874 1/20 0.48
F7 P08709 1/20 0.46
F3 P13726 1/20 0.46
GPR183 P32249 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4318603 1.00 HRH4 (0.65) HRH4HRH3HRH1KMT2AMEN1
SCHEMBL4322536 1.00 HRH4 (0.65) HRH4HRH3HRH1KMT2AMEN1
Hydrochloric Acid SCHEMBL4486274 0.99 HRH4 (0.64) HRH4HRH3HRH1KMT2AMEN1
Hydrochloric Acid SCHEMBL4495185 0.99 HRH4 (0.64) HRH4HRH3HRH1KMT2AMEN1
Hydrochloric Acid SCHEMBL4486279 0.99 HRH4 (0.64) HRH4HRH3HRH1KMT2AMEN1
SCHEMBL13815897 0.87 HRH4 (0.76) HRH4HRH3HRH1KMT2AMEN1
SCHEMBL4319461 0.87 NPC1 (0.59) HRH4HRH3KMT2AMEN1RAB9A
SCHEMBL4476320 0.87 HRH4 (0.54) HRH4HRH3KMT2AMEN1RAB9A
SCHEMBL4338442 0.87 HRH4 (0.54) HRH4HRH3KMT2AMEN1RAB9A
SCHEMBL4319459 0.87 NPC1 (0.59) HRH4HRH3KMT2AMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2010172-B1 INDOLES AND BENZOIMIDAZOLES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2012-08-29 EP claimed
US-7544698-B2 Indoles and benzoimidazoles as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA, N.V. (BE) 2009-06-09 US claimed
EP-2010172-A2 INDOLES AND BENZOIMIDAZOLES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR Janssen Pharmaceutica, N.V. (BE) 2009-01-07 EP claimed
WO-2007117401-A2 INDOLES AND BENZOIMIDAZOLES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2007-10-18 WO claimed
US-20070238771-A1 Indoles and benzoimidazoles as histamine H4 receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2007-10-11 US claimed
EP-2010172-B1 INDOLES AND BENZOIMIDAZOLES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2012-08-29 EP disclosed
US-7544698-B2 Indoles and benzoimidazoles as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA, N.V. (BE) 2009-06-09 US disclosed
US-20070238771-A1 Indoles and benzoimidazoles as histamine H4 receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2007-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238771-A1 Indoles and benzoimidazoles as histamine H4 receptor modulators HRH4, HRH3, HRH1 HRH4 1/4885HRH3 2/4885HRH1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.